StemCell Therapy

A new market report by Verified Market Research on the Regenerative Medicine Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Regenerative Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=COD&utm_medium=007

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Regenerative Medicine manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Regenerative Medicine Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=COD&utm_medium=007

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Regenerative Medicine. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Verified Market Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=COD&utm_medium=007

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Regenerative Medicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Read the original here:
Regenerative Medicine Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 - Cole of...

TORONTO and MARLBOROUGH, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- With Health Canada and the Food and Drug Administration beginning to approve and reimburse cell and gene therapies in significant numbers, the demand for cell and viral vector manufacturing will continue to grow. Consequently, the industrialization challenges associated with the variability of cell and gene therapies, and with manufacturing them on a commercial scale, must be overcome. CCRM and Cytiva, formerly part of GE Healthcare Life Sciences, have renewed their Collaboration Agreement for continued operation of the Centre for Advanced Therapeutic Cell Technologies (CATCT), which was created to accelerate the development and adoption of cell manufacturing technologies for novel regenerative medicine-based therapies.

Together, CCRM and Cytiva have established a commercialization hub where great minds, state-of-the-art equipment and a spirit of innovation meet, says Michael May, President and CEO of CCRM. Continuing to partner in the operation of CATCT will enable us to move the cell and gene therapy industry closer to fulfilling its promise of creating cures, and enabling treatments to get to patients.

By creating an innovative platform and approach to tackle the issues facing commercialization of living therapies, we are supporting the viability of the regenerative medicine industry, says Catarina Flyborg, Vice President, Cell & Gene Therapy, Cytiva. In CATCT, we are creating the technologies, processes and equipment that will enable our customers, and the broader industry, to achieve its goals and help patients.

Established in 2016, CATCT is a partnership between CCRM and Cytiva, with initial funding from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). Its staff of 40 works in a 10,000 ft (~930 m) process development facility, located in the MaRS Discovery District, next to Torontos world-leading hospitals and the University of Toronto.

The global regenerative medicine market was valued at US$23.8 billion (2018), and it is anticipated to grow to US$151 billion by 2026 with an annual growth rate of 26.1 per cent.i Operating CATCT allows CCRM and Cytiva to address the manufacturing bottlenecks that would otherwise have the potential to impede the industrys growth.

CATCTs key areas of expertise are:

The work conducted in CATCT can be categorized as follows: the first is fee-for-service development projects that advance customers therapeutic technologies towards industrialization; second, the teams New Product Introductions (NPIs) efforts provide core biological expertise in Cytivas product development process; finally, internal technology development builds additional capabilities and innovative solutions for cell and gene therapies.

A recent success stemming from the work being done in CATCT is the involvement of CCRM and Cytiva in a consortium led by iVexSol Canada, with conditional funding from Next Generation Manufacturing Canada (NGen), to build an advanced manufacturing platform for lentiviral vectors. As core partners in this consortium, which was announced in August 2019, CCRM will provide supporting manufacturing infrastructure and downstream processing capabilities, and Cytiva will share expertise of manufacturing processes, and access to and use of specialized tools and technology.

The new collaboration agreement between CCRM and Cytiva has a three-year term and it became effective on October 15, 2019. The funding will be a combination of in-kind contributions, milestone payments, reinvested fee-for-service revenue and any successful grant opportunities. FedDevs funding of CATCT was for a three-year term and ended in December 2018.

About CCRM CCRM, a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Torontos Medicine by Design. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.

About CytivaCytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit http://www.cytiva.com for more.

For more information, please contact:

Stacey JohnsonDirector, Communications and Marketing, CCRM416-946-8869stacey.johnson@ccrm.ca

Colleen ConnollySenior Communications Manager, Cytiva774-245-3893Colleen.Connolly@cytiva.com

ihttps://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

View post:
Toronto centre solving cell manufacturing challenges to benefit patients and global industry CCRM and Cytiva, formerly part of GE Healthcare Life...

The month of May 2020 was an exciting month for oncology with many updates from the FDA. In particular, the FDA granted 4 approvals on Friday, May 15, 2020 alone. Eight additional approvals were granted throughout the month. Among other FDA news this month, the FDA granted a Priority Review, 2 Orphan Drug designations, a Breakthrough Therapy designation, a Fast Track designation, a Regenerative Medicine Advanced Therapy designation, and more.

FDA Approves EIS System Nevisense 3.0 for the Early Detection of Melanoma

On May 1, 2020, the FDA granted approval to an electrical impedance spectroscopy system, Nevisense 3.0, the third-generation of the SciBase Nevisense system, for the early detection of melanoma. Nevisense uses an AI-based point-of-care system for a non-invasive procedure to evaluate irregular moles and is the only FDA-approved system available in the United States for the detection of melanoma.

FDA Grants Priority Review to Oral Hypomethylating Agent for Frontline Maintenance in AML

The FDA granted Priority Review on May 1, 2020, to an investigational oral hypomethylating agent, CC-486, as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a complete remission (CR) or CR with incomplete blood count recovery after receiving induction therapy with or without consolidation therapy.

FDA Grants Orphan Drug Designation to HQP1351 in Chronic Myeloid Leukemia

On May 4, 2020, the FDA granted an Orphan Drug designation to a third-generation BCR-ABL inhibitor, HQP1351, as treatment of patients with chronic myeloid leukemia.

FDA Extends Target Action Date for Liso-cel in R/R Large B-cell Lymphoma

The action date for the CD19-directed chimeric antigen receptor (CAR) T cell therapy lisocabtagene maraleucel (liso-cel) as treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least 2 therapies, was extended 3 months by the FDA. The updated Prescription Drug User Fee Act (PDUFA) action date is November 16, 2020, according to an announcement on May 6, 2020.

FDA Grants Orphan Drug Designation to First Liver-Targeted Drug for HCC

On May 6, 2020, MIV-818, was granted an Orphan Drug Designation by the FDA for the treatment of patients with hepatocellular carcinoma, which follows an Orphan Medicinal Drug designation in Europe for the same indication, which was granted in April 2020 by the Committee for Orphan Medicinal Products, a division of the European Medicines Agency.

FDA Approves Capmatinib in MET Exon 14+ Metastatic Non-Small Cell Lung Cancer

The FDA granted approval on May 6, 2020, to capmatinib (Tabrecta) for adult patients with metastatic nonsmall cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test.

FDA Grants RMAT Designation to Ilixadencel in Metastatic RCC

On May 8, 2020, the FDA granted a Regenerative Medicine Advanced Therapy designation to ilixadencel, as treatment of metastatic renal cell carcinoma.

FDA Approves Maintenance Olaparib/Bevacizumab in Advanced Ovarian Cancer

The FDA granted approval on May 8, 2020, to the combination of olaparib (Lynparza) and bevacizumab (Avastin) for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiencypositive status defined by either a deleterious or suspected deleteriousBRCAmutation, and/or genomic instability.

FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers

On May 9, 2020, the FDA approved selpercatinib (formerly known as LOXO-292; Retevmo) capsules for the treatment of patients with lung cancer or thyroid cancer harboringRETalterations, marking the first treatment approved by the FDA to targetRETgene alterations.

FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan in HER2+ Gastric Cancer

The FDA granted a Breakthrough Therapy designation on May 11, 2020, to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received 2 or more prior regimens including trastuzumab.

FDA Halts Review of BLA for Ide-cel in R/R Multiple Myeloma Pending Additional Data

On May 13, 2020, the FDA issued a Refusal to File letter regarding the Biologics License Application for the CAR T-cell agent, idecabtagene vicleucel (ide-cel), which was submitted in March 2020 as a potential treatment for patients with heavily pretreated relapsed or refractory multiple myeloma. A preliminary review was carried out by the FDA, but it was realized that the Chemistry, Manufacturing, and Control module of the BLA required more information before the review could be completed.

FDA Denies Approval of Avapritinib in Fourth-Line GIST

The FDA issued a complete response letter (CRL) to Blueprint Medicines, Inc regarding the New Drug Application for avapritinib (Ayvakit) as treatment of adult patients with unresectable or metastatic fourth-line gastrointestinal stromal tumor. The CRL denies approval of the application.

FDA Approves Pomalidomide for Treatment of Kaposi Sarcoma

On May 15, 2020, the FDA granted approval to pomalidomide (Pomalyst) for the treatment of patients with acquired immunodeficiency syndromesrelated Kaposi sarcoma who have developed resistance to highly active antiretroviral therapy, or those with Kaposi sarcoma who are human immunodeficiency virusnegative.

FDA Approves Nivolumab/Ipilimumab Combo for Advanced PD-L1+ NSCLC

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) on May 15, 2020, for the treatment of patients with metastatic or recurrent NSCLC whose tumors express PD-L1 (1%), as determined by an FDA-approved test, and who do not have anEGFRorALKtumor aberration.

FDA Approves Rucaparib for BRCA1/2-Mutant mCRPC

On May 15, 2020, the FDA has approved rucaparib (Rubraca) the treatment of adult patients with a deleteriousBRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

Ripretinib Receives FDA Approval for Treatment of Advanced GIST

On May 15, 2020, the FDA has granted approval to ripretinib (Qinlock) for the treatment of adult patients with advanced gastrointestinal stromal tumor who had at least 3 prior lines of therapy with kinase inhibitors, including imatinib (Gleevec). The approval is 3 months ahead of the Prescription Drug Fee Act target action date.

FDA Approves Atezolizumab Monotherapy in Advanced PD-L1-High NSCLC

The FDA granted approval on May 18, 2020, to atezolizumab (Tecentriq) monotherapy as treatment for adults with metastatic nonsmall cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining on 50% of tumor cells [TC 50%] or PD-L1 staining on tumor-infiltrating immune cells [IC] covering 10% of the tumor area [IC 10%]), as determined by an FDA-approved test, and have noEGFRorALKgenomic tumor aberrations. This approval marks the fifth indication for atezolizumab in metastatic NSCLC and lung cancer in general, Genentech announced in a press release.

Trastuzumab Deruxtecan Receives Orphan Drug Designation from FDA for Gastric Cancer

The FDA granted an Orphan Drug designation to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with gastric or gastroesophageal junction cancer on May 22, 2020.

FDA Approves Brigatinib as Frontline Treatment of ALK-Positive Metastatic NSCLC

On May 22, 2020, the FDA has granted approval to brigatinib (Alunbrig) for the frontline treatment of patients withALK-positive metastatic NSCLC, as detected by an FDA-approved test.

FDA Approves Frontline Nivolumab/Ipilimumab/Chemo for Advanced NSCLC

The FDA has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) with limited platinum-doublet chemotherapy for the frontline treatment of patients with metastatic or recurrent NSCLC who do not have EGFR or ALK genomic tumor aberrations, according to an announcement on May 26, 2020.

FDA Cancels ODAC Meeting for BLA of Margetuximab in HER2+ Breast Cancer

On May 28, 2020, the FDA has announced that they will no longer hold an Oncologic Drugs Advisory Committee meeting to discuss the Biologics License Application for margetuximab (MGAH22) in combination with chemotherapy as a potential treatment of patients with HER2-positive breast cancer. However, the FDA still plans to meet the Prescription Drug User Fee Act date of December 18, 2020, for the application review.

Onvansertib Receives FDA Fast Track Designation in KRAS+ mCRC

The FDA granted a Fast Track designation to onvansertib for the second-line treatment of patients withKRAS-mutant metastatic colorectal cancer in combination with FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) and bevacizumab (Avastin) on May 28, 2020.

FDA Approves Atezolizumab Combo for Unresectable or Metastatic Hepatocellular Carcinoma

The FDA granted approval to atezolizumab in combination with bevacizumab as treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not had a prior systemic therapyon May 29, 2020.

Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review

Pralsetinib (BLU-667) was granted a priority review on May 29, 2020, for the treatment of patients with advanced solid tumors harboring RETalterations, with a plannedaction date of November 23, 2020.

FDA Approves Frontline Ramucirumab/Erlotinib for EGFR+ mNSCLC

The FDA approved ramucirumab (Cyramza) in combination with erlotinib (Tarceva) for the first-line treatment of patients with metastatic NSCLC harboringEGFRexon 19 deletions or exon 21 (L858R) mutations on May 30, 2020, marking this the only antiVEGFR/EGFR tyrosine kinase inhibitor combination regimen approved by the FDA for the treatment of patients withEGFR-mutant metastatic NSCLC.

Follow this link:
A Look Back at the FDA News from May 2020 - Targeted Oncology

FINDINGS

Newswise Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group known as Gleason grade group 5 and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.

One subtype, which accounts for about 15% of the grade group 5 cancers, has highly aggressive features and is associated with much worse outcomes than the other subtypes. Another, which makes up about 20% of the tumors, appears to be much less aggressive and may not require intensified and aggressive treatments. Traditionally, all tumors in Gleason grade group 5 have been treated in the same way.

BACKGROUND

Prostate cancer is the leading solid-tumor cancer among men in the United States and a major cause of morbidity globally. While early-stage, localized prostate cancer is curable, current treatments dont always work for everyone. To find out why standard treatment may work for some and not others, the UCLA researchers looked at tumors in the Gleason grade group 5 subset of prostate cancer. These tumors are at the highest risk to fail standard treatment, leading to metastasis and death. The researchers thought that studying the gene expression the unique signature of each cancer cell in these tumors might provide insight into how to make treatments more personalized for each patient.

METHOD

The researchers first analyzed data from more than 2,100 Gleason grade group 5 tumors, looking at how the genetic blueprints differed among the tumors. They identified distinct clusters of subgroups and validated their findings by analyzing an additional cohort of more than 1,900 Gleason grade group 5 prostate cancers.

IMPACT

By using the genetic information from tumors in men with prostate cancer, physicians hope to one day create more personalized treatments based on the actual characteristics of the cancer. This information will help optimize quality of life and avoid overtreating subgroups of men who may not need aggressive treatments.

AUTHORS

The studys lead author is Dr. Amar Kishan, an assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center. The co-senior authors are Dr. Joanne Weidhaas, a professor of radiation oncology and director of translational research at the Geffen School of Medicine, and Paul Boutros, a professor of urology and human genetics and director of cancer data science for the Jonsson Cancer Center. Boutrosis also a member of the UCLA Institute of Urologic Oncology and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Other UCLA authors include David Elashoff, Dr. Rob Reiter and Dr. Matthew Rettig.

JOURNAL

Thestudy was publishedin the journal European Urology.

FUNDING

The research was funded in part by an award from the American Society for Radiation Oncology and the Prostate Cancer Foundation, the Radiological Society of North America, and the National Institutes of Health.

Continued here:
Some types of prostate cancer may not be as aggressive as originally thought - Newswise

The global Biobanking Market was valued at USD 1.54 billion in 2016 and is projected to reach USD 2.88billion by 2025, growing at a CAGR of 7.2% from 2017 to 2025.

A biobank is a type of biorepository that stores biological samples (usually human) for use in research. The market for Biobanks has seen a rise in the market values because of increasing awareness amongst young parents regarding storage of stem cells for regenerative purposes. Also, the increased funds of govt. in research and development of Genetically Modified Products is also a key factor in driving the market positively.

The Final Report will cover the impact analysis of COVID-19 on this industry:

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10059470

Sample Infographics:

Market Dynamics:1. Market Drivers1.1 More focus on Genetic disease treatment and Research activities1.2 Growing popularity of stem cell banking from placental cord of new born1.3 Demand of regenerative medicines1.4 Cost effective drug discovery researches and project2. Market Restraints2.1 High cost of technical Instruments2.2 Difficulty in procurement of Biological samples

Market Segmentation:1.Global Biobanking Market, by Sample Type:1.1 Blood Products1.2 Human Tissues1.3 Cell Lines1.4 Nucleic Acids1.5 Biological Fluids1.6 Human Waste Products

2. Global Biobanking Market, by Application:2.1 Regenerative Medicine2.2 Life Science Research2.3 Clinical Research

View Source Of Related Reports:

Biobanking MarketViral Inactivation MarketVirus Filtration MarketViral Clearance MarketVeterinary-Animal Vaccines MarketVaccine Adjuvants MarketTerahertz and Infrared Spectroscopy MarketTangential Flow Filtration MarketSterile Filtration MarketStem Cell Banking Market Stem Cell Assay Market

3. Global Biobanking Market, by Products and services:3.1 Equipment3.1.1 Storage3.1.2 Sample analysis3.1.3 Sample Processing3.1.4 Sample Transportation3.2 Consumables3.2.1 Storage3.2.2 Analysis3.2.3 Processing3.2.4 Collection3.3 Services3.3.1 Storage Services3.3.2 Processing Services3.3.3 Transport Services3.3.4 Supply Services3.4 Software

4. Global Biobanking Market, by Application:4.1 Manual4.2 Automated

5. Global Biobanking Market, by Region:5.1 North America (U.S., Canada, Mexico)5.2 Europe (Germany, UK, France, Rest of Europe)5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)5.4 Latin America (Brazil, Argentina, Rest of Latin America)5.5 Middle East & Africa

Competitive Landscape:The major players in the market are as follows:1. Thermo Fisher Scientific Inc.2. Panasonic Healthcare Holdings Co., Ltd.3. Becton, Dickinson and Company4. Qiagen N.V.5. Merck KGaA6. VWR Corporation7. Tecan Trading AG8. Brooks Automation, Inc.9. Chart Industries, Inc.10. Hamilton Company11. Greiner Holding AG12. Promega CorporationThese major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10059470

RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH:Research study on the Biobanking Marketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the research methodology of verified market research and other aspects of the research study, kindly get in touch with our sales team.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research

Email:[emailprotected]

Phone: +1 313 462 0609

Excerpt from:
Biobanking Market Is Projected To Grow Vibrantly In The Upcoming Years 2020-2025 (Impact of COVID-19) - Cole of Duty

Law360 (June 4, 2020, 4:18 PM EDT) -- Precision medicine has the potential to transform health care but also presents significant challenges from a regulatory perspective. In this article, we explore the federal fraud and abuse pitfalls inherent in certain precision medicine arrangements, particularly those affecting health systems and hospitals and clinical laboratories with which they routinely partner to perform genomic testing.

Precision medicine, sometimes referred to as personalized medicine, is the future of patient care, and has increasingly become a focal point for hospitals and health systems across the U.S. While the concept of accurate and precise medicine is not new,[1] advances in the fields of regenerative medicine,...

In the legal profession, information is the key to success. You have to know whats happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

TRY LAW360 FREE FOR SEVEN DAYS

View post:
Beware Fraud And Abuse Pitfalls In Precision Medicine - Law360

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer.

We are excited to welcome Stacy to the ImmunoGen leadership team as mirvetuximab soravtansine moves through registration studies and our early-stage pipeline continues to advance, said Mark Enyedy, ImmunoGens President and Chief Executive Officer. Stacy is a proven business leader with broad corporate strategy and business development expertise, and will play an important role in our organization as we continue to execute against our strategy, explore new opportunities for our pipeline, and seek to bring mirvetuximab to patients as quickly as possible.

Ms. Coen brings over 20 years of business and corporate development experience from leading oncology and rare disease companies. She joins ImmunoGen from Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntingtons Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.

I am delighted to join ImmunoGen as the Company works to bring its first product to market and advance a portfolio of novel ADCs, said Ms. Coen. I look forward to working with the talented team at ImmunoGen and contributing to the goal of delivering more good days to people living with cancer.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to target a better now.

Learn more about who we are, what we do, and how we do it at http://www.immunogen.com.

FORWARD LOOKING STATEMENTS

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGens expectations related to the advancement of ImmunoGens research and development programs and Ms. Coens potential contributions to ImmunoGen. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGens actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of ImmunoGens pre-clinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of pre-clinical studies, clinical trials, and regulatory processes; ImmunoGens ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting impact on ImmunoGens industry and business; and other factors more fully described in ImmunoGens Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the Securities and Exchange Commission.

See the original post:
ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer - Business Wire

The global Regenerative Medicine market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Regenerative Medicine market player in a comprehensive way. Further, the Regenerative Medicine market report emphasizes the adoption pattern of the Regenerative Medicine across various industries.

The Regenerative Medicine market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Regenerative Medicine market provides a birds eye view of the current proceeding within the Regenerative Medicine market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Regenerative Medicine market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2656563&source=atm

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Regenerative Medicine market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Regenerative Medicine market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Regenerative Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Regenerative Medicine market.The following players are covered in this report:DePuy SynthesMedtronicZimmerBiometStrykerAcelityMiMedx GroupOrganogenesisUniQureCellular Dynamics InternationalOsiris TherapeuticsVcanbioGamida CellGolden MeditechCytoriCelgeneVericel CorporationGuanhao BiotechMesoblastStemcell TechnologiesBellicum PharmaceuticalsRegenerative Medicine Breakdown Data by TypeCell TherapyTissue EngineeringBiomaterialOtherRegenerative Medicine Breakdown Data by ApplicationDermatologyCardiovascularCNSOrthopedicOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2656563&source=atm

The Regenerative Medicine market report offers a plethora of insights which include:

The Regenerative Medicine market report answers important questions which include:

The Regenerative Medicine market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2656563&licType=S&source=atm

Why Choose Regenerative Medicine Market Report?

Regenerative Medicine Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See the article here:
Coronavirus threat to global Regenerative Medicine Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2023 - News...

A local hospital is using a little-known medicine to treat COVID-19 patients after the FDA authorized compassionate use approval to administer the drug.

Landmark Hospital of Athens treated two patients with its first doses of the medicine last week, according to a press release from Landmark Hospitals, which operates six long-term acute-care hospitals in the Southeast, including its Athens hospital on Sunset Drive.

The medicine, called Organicell Flow, is a biologic product derived from amniotic fluid, which contains stem cells. Amniotic fluid is the protective fluid in the sac containing growing fetuses.

Landmark is providing the product to patients with advanced COVID-19 conditions, according to the company.

After receiving Organicell Flow intravenously last week, the two patients were clinically stable as of Wednesday, according to Landmark.

Organicell Regenerative Medicine of Boca Raton, Fla., manufactures the medicine from human amniotic fluid voluntarily donated during Cesarean section surgeries, according to Landmark.

Developed to promote wound healing, Organicell Flow contains more than 300 growth factors, cytokines and chemokines, as well as hyaluronic acid and exosomes, according to the press release.

The medicine can modulate a patients immune response. In some COVID-19 patients, their supercharged immune response can be as harmful as the actual coronavirus that causes COVID-19.

The condition, called cytokine storm syndrome, can damage lungs and other organs and can lead to death, said Landmark Hospitals Chairman Dr. William Kapp.

The data collected from the patients receiving compassionate use treatments will guide us to interventions that modulate COVID-19 immune response in the lungs and reduce systemic organ damage, Kapp said in Landmarks press release.

Organicell Flow is one of a number of medicines health providers around the world are trying out to treat COVID-19, which has claimed more than 100,000 lives in the United States so far and nearly 2,000 in Georgia.

Two other Athens hospitals have also recently received shipments of another drug that may help patients with COVID-19, remdesivir.

Gov. Brian Kemp announced earlier this week that the state was distributing more than 18,000 vials of remdesivir to more than 80 Georgia hospitals, enough to treat nearly 17,000 patients. The hospitals include Athens St. Marys Healthcare System and the Piedmont system that includes Piedmont Athens Regional and several other Georgia hospitals.

Remdesivir is being used to treat patients with serious symptoms such as low oxygen levels or pneumonia, according to the Georgia Department of Public Health.

Developed to treat people with Ebola virus disease, remdesivir has been shown to shorten the time of recovery from COVID-19 illness in hospitalized patients, but in the absence of thorough studies is considered investigational.

Standard treatment for COVID-19 includes oxygen therapy, mechanical ventilation and medicine to maintain blood pressure.

Read the original post:
Athens hospital using biologic treatment on COVID-19 patients - Online Athens

A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA.

Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo.

Successfully growing human cells in mouse embryos might one day help scientists understand the growth and aging process of our bodies and how diseases such as COVID-19 damage cells and could eventually even serve as a scaffold to grow organs for transplantation, Feng said.

Related: The 9 most interesting transplants

Feng and his team tackled a long-standing issue in creating such chimeras: that in order for human embryonic stem cells and mouse embryonic stem cells to chat and mingle, they needed to be in the same state of development. Embryonic stem cells are pluripotent, meaning they can develop into any type of cell in the body.

But "the human embryonic stem cell looks and behaves very differently from the mouse embryonic stem cell," so past attempts to get them to comingle have all failed, Feng told Live Science. At first, researchers thought the failures were due to some kind of species barrier; but after many years of study, they realized that it wasn't a species issue, but rather a maturity one.

The human stem cells were in a later stage of development called a "primed" state, which normally occurs only after the human embryo has already been implanted in the uterine wall. In contrast, the mouse stem cells were in a more "naive" state, which normally occurs when the mouse embryo is still floating around in the fallopian tubes. In the past, researchers weren't able to convert human cells back to this naive state, Feng said.

In their experiments, Feng and his team were inspired by a process called "embryonic diapause" that occurs in hundreds of mammals from bears to mice: When there's some sort of hardship such as a famine or shortage of water, some animals' embryos can remain in the naive state inside a mother's fallopian tubes for months and sometimes over a year for the environment to become more suitable, Feng said.

It's not clear what triggers the embryos to pause in this state, but a protein called mTOR seems to be a sensor that detects when conditions are bad, he said. Feng and his team figured out that they could target this protein inside human stem cells to make the cells think that they were experiencing famine, and needed to jump to a more naive state where they could conserve energy, Feng said.

The protein mTOR normally promotes the production of proteins and other molecules to support cell growth and proliferation, so by inhibiting it, Feng and his team "shocked" the human cells into changing their metabolism and gene expression. "So it behaves pretty much like the mouse cell," Feng said. What resulted was a naive set of human stem cells that could be cultured together with mouse stem cells and "intermingle very nicely," Feng said. The researchers then injected 10 to 12 of these naive human stem cells into mouse embryos.

In most of the mouse embryos, the naive human stem cells successfully developed into mature human cells in all three germ layers: the ectoderm, or the primary cell layers that develop when the embryo is growing and which later develop to form hair, nails, the epidermis and nerve tissue; the mesoderm, or the cells that make up the organs; and the endoderm, or the inner lining of organs. But no human cells spilled over into germline tissue, which develops into egg and sperm cells.

These germ layers then developed into more differentiated cells, and when the researchers stopped their experiment on the 17th day, 14 embryos were between 0.1% and 4% human (some had less human cells and some had more), with human cells found through the embryo, including in the liver, heart, retina and red blood cells.

Related: First pig-monkey chimeras were just created in China

But what was really "surprising" was the speed at which the human cells developed, Feng said. For example, the embryos were able to generate human red blood cells in 17 days, compared to the roughly 56 days red blood cells take to develop in a growing human embryo. Similarly, human eye cells don't develop until much later on in the embryo, whereas within 17 days, human eye cells including photo receptors formed in the chimera. Basically, the human cells "assumed the clock of the mouse embryo," Feng said. Previously, scientists thought this accelerated development was impossible because the tempo of human cell development was always thought to be "kind of immutable," he added.

This paper identifies a "novel way" of turning primed human pluripotent stem cells into a naive state, said Ronald Parchem, an assistant professor in the Stem Cells and Regenerative Medicine Center at Baylor College of Medicine in Texas, who was not a part of the study. But "the level of chimerism is low in this study," compared to another study that developed chimeras with up to 20% human cells per embryo, he said. That study, however, was published to the preprint database Biorxiv on May 24,and hasn't yet been peer-reviewed. "Together, these studies provide insight into capturing pluripotent states in vitro and highlight the barriers preventing successful cross-species chimerism," Parchem said. "Identifying ways to overcome these barriers has the potential to improve regenerative medicine."

These findings might "stimulate research" in the fundamental understanding of human development, especially how time is measured by biological systems, Feng said. Such chimeras could help scientists understand human diseases. For example, researchers might one day be able to regenerate human blood in a mouse model and study diseases such as malaria. Or if you can create human lung cells, or epithelial cells that line the respiratory tract, that mouse can become a "model system" for studying diseases like COVID-19, Feng said. In other words, mice with human cells can be infected with COVID-19 to understand how the virus attacks the body.

The most cited potential application of such chimeras is organ growth. But this likely won't happen in mice but much larger animals such as pigs, he said. Of course, these applications raise ethical issues, he added. One such ethical consideration is that chimeras blur the lines between species and that makes it difficult to determine the morality or the consciousness that those animals possess. For example, chimeras used in animal testing could be given too many human characteristics and have a similar moral status or consciousness to us, according to a previous Live Science report.

Feng said that much discussion needs to take place before such applications can be considered.

"This field requires much more exploration before this becomes a reality," said Carol Ware, the associate director at the University of Washington's Institute for Stem Cell and Regenerative Medicine, who was also not a part of the study. "A couple of the primary hurdles at this point are determining the host species for these human cells," and public acceptance in the work, she added.

"At this point, it would seem that the speed with which this clinical opportunity will become a reality will not be hindered by the ability to grow human organs," she added. "I would have liked to see," what happens when mTOR is taken away inside the lab dish and these naive human cells are allowed to advance again, particularly to see if some key cellular processes resume again, she added.

The findings were published in the journal Science Advances on May 13.

Originally published on Live Science.

See original here:
New human-mouse chimera is the most human yet - Livescience.com

BAR HARBOR Research by scientists at the MDI Biological Laboratoryis opening up new approaches to promoting tissue regeneration in organs damaged by disease or injury.

In recent years, research in regenerative biology has focused on stem cell therapies that reprogram the bodys own cells to replace damaged tissue, which is a complicated process because it involves turning genes in the cells nucleus on and off.

A recent paper in the journal Genetics by MDI Biological Laboratory scientist Elisabeth Marnik, Ph.D., a postdoctoral fellow in the laboratory of Dustin Updike, Ph.D., offers insight into an alternate pathway to regeneration: by recreating the properties of germ cells.

Germ cells, which are the precursors to the sperm and egg, are considered immortal because they are the only cells in the body with the potential to create an entirely new organism. The stem cell-like ability of germ cells to turn into any type of cell is called totipotency.

By getting a handle on what makes germ cells totipotent, we can promote regeneration by unlocking the stem cell-like properties of other cell types, said Updike. Our research shows that such cells can be reprogrammed by manipulating their cytoplasmic composition and chemistry, which would seem to be safer and easier than changing the DNA within a cells nucleus.

Using the tiny, soil-dwelling nematode worm, C. elegans, as a model, the Updike lab studies organelles called germ granules that reside in the cytoplasm (the contents of the cell outside of the nucleus) of germ cells. These organelles, which are conserved from nematodes to humans, are one of the keys to the remarkable attributes of germ cells, including the ability to differentiate into other types of cells.

In their recent paper entitled Germline Maintenance Through the Multifaceted Activities of GLH/Vasa in Caenorhabditis elegans P Granules, Updike and his team describe the intriguing and elusive role of Vasa proteins within germ granules in determining whether a cell is destined to become a germ cell with totipotent capabilities or a specific type of cell, like those that comprise muscle, nerves or skin.

Because of the role of Vasa proteins in preserving totipotency, an increased understanding of how such proteins work could lead to unprecedented approaches to de-differentiating cell types to promote regeneration; or alternatively, to new methods to turn off totipotency when it is no longer desirable, as in the case of cancer.

The increase in chronic and degenerative diseases caused by the aging of the population is driving demand for new therapies, said MDI Biological Laboratory President Hermann Haller, M.D. Dustins research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent, as well as an increased understanding of cancer.

Because of the complexity of the cellular chemistry, research on Vasa and other proteins found in germ granules is often overlooked, but that is rapidly changing especially among pharmaceutical companies as more scientists realize the impact and potential of such research, not only for regenerative medicine but also for an understanding of tumorigenesis, or cancer development, Updike said.

Recent research has found that some cancers are accompanied by the mis-expression of germ granule proteins, which are normally found only in germ cells. The mis-expression of these germ-granule proteins seems to promote the immortal properties of germ cells, and consequently tumorigenesis, with some germ-granule proteins now serving as prognosis markers for different types of cancer, Updike said.

Updike is a former postdoctoral researcher in the laboratory of Susan Strome, Ph.D., at University of California, Santa Cruz. Strome, who was inducted into the National Academy of Sciences last year, first discovered P granules more than 30 years ago. She credits Updike, who has published several seminal papers on the subject, with great imagination, determination and excellent technical skill in the pursuit of his goal of elucidating the function and biochemistry of these tiny organelles.

The lead author of the new study from the Updike laboratory, Elisabeth A. Marnik, Ph.D., will be launching her own laboratory at Husson University in Bangor, Maine, this fall. Other contributors include J. Heath Fuqua, Catherine S. Sharp, Jesse D. Rochester, Emily L. Xu and Sarah E. Holbrook. Their research was conducted at the Kathryn W. Davis Center for Regenerative Biology and Medicine at the MDI Biological Laboratory.

Updikes research is supported by a grant (R01 GM-113933) from the National Institute of General Medical Sciences (NIGMS), an institute of the National Institutes of Health (NIH). The equipment and cores used for part of the study were supported by NIGMS-NIH Centers of Biomedical Research Excellence and IDeA Networks of Biomedical Research Excellence grants P20 GM-104318 and P20 GM-203423, respectively.

We aim to improve human health and healthspan by uncovering basic mechanisms of tissue repair, aging and regeneration, translating our discoveries for the benefit of society and developing the next generation of scientific leaders. For more information, please visitmdibl.org.

See the original post:
Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis - Bangor Daily News

A report, added to the extensive database of verified Market Research titled Regenerative Medicine Market 2020 by Manufacturer, Region, Type and Application, Forecast up to 2026, is intended to highlight first-hand documentation of all the best implementations in the industry. The report contains an in-depth analysis of current and future market trends, segmentation, industrial opportunities and the future market scenario, taking into account the forecast years 2020 to 2026. It contains extremely important details on the key players in the Regenerative Medicine market as well as growth-oriented practices, that they normally use. The report examines a number of growth drivers and limiting factors. The key forecast information by region, type and application with sales and revenue from 2020 to 2026 is included in this report.

Request Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=WCS&utm_medium=001

Top 10 Companies in the Regenerative Medicine Market Research Report:

Competitive landscape:

The report examines the major players, including the profiles of the major players in the market with a significant global and / or regional presence, combined with their information such as related companies, downstream buyers, upstream suppliers, market position, historical background and top competitors based on the Sales with sales contact information.

Regional Description:

The Regenerative Medicine market was analyzed and a proper survey of the market was carried out based on all regions of the world. The regions listed in the report include: North America (United States, Canada, and Mexico), Europe (Germany, France, United Kingdom, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina , Colombia etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa). All these regions have been studied in detail and the prevailing trends and different possibilities are also mentioned in the market report.

Sales and sales broken down by application:

Sales and sales divided by type:

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Regenerative Medicine market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=WCS&utm_medium=001

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution

6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=WCS&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

More:
Impact of Covid-19 Outbreak on Regenerative Medicine Market 2020 Trends, Growth Opportunities, Demand, Application, Top Companies and Industry...

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Regenerative Medicine Market to Witness a Pronounce Growth During 2017 to 2025 - 3rd Watch News

Global Regenerative Medicine market offers a detailed overview of the regional as well as local market. With the objective to offer a complete market overview the Regenerative Medicine market report includes regional competitive landscape for the number of major market service providers. Moreover, the Regenerative Medicine market report also provides a comprehensive analysis of the major market players in the regional and global regions. The Regenerative Medicine market report provides an in-depth analysis of the market growth aspects, opportunities, status, size in terms of value and volume, and market segmentation along with the market revenue. In addition, the report also studies market outlook and status of the global and major regions on the basis of product, application, and key market players.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/52

Additionally, the research report on Regenerative Medicine market provides a broad analysis of the market which includes market overview, production, producers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of the global Regenerative Medicine market. On the other hand, the Regenerative Medicine market report also studies the market status for the forecast period.

However, this will help to increase the marketing opportunities across the world as well as major market providers. The global Regenerative Medicine market report also offers in depth coverage from the huge range of aspects as well as scenario to opportunities and future trends. The global Regenerative Medicine market report also contains the manufacturers data which may comprise price, shipment, revenue, interview record, gross profit, and business distribution which help the customers to know about the global Regenerative Medicine market competitive landscape better.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

The Regenerative Medicine market research report also covers the extensive SWOT analysis, venture return investigation, and speculation attainability investigation. The Regenerative Medicine market report further describes a complete market dynamic such as opportunities, market drivers, as well as challenges prevalent in the global market to better understand the Regenerative Medicine market more deeply. In addition to this, the Regenerative Medicine market report also offers qualitative as well as qualitative analysis of very segment along with its revenues and investment details in the market. The Regenerative Medicine market research report also describes the leading continents as well as their major countries with the profiles of major players operating across the global market.

In addition to this, the Regenerative Medicine market report also provides helpful insights for every established and innovative players across the globe. Furthermore the Regenerative Medicine market report offers accurate analysis for the shifting competitive dynamics. This research report comprises a complete analysis of future growth in terms of the evaluation of the mentioned forecast period. The Regenerative Medicine market report offers a comprehensive study of the technological growth outlook over time to know the market growth rates. The Regenerative Medicine market report also includes progressive analysis of the huge number of different factors that are boosting or operating as well as regulating the Regenerative Medicine market growth.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

View post:
Regenerative Medicine Market 2020 Size, Share, Regional Growth, Trends, Methods, Applications, Equipment vendors, Business Prospects and Forecast to...

Meat the Future is a slightly goofy title for a film that takes its subject very, very seriously. The wordplay feels like a token flourish of whimsy in Liz Marshalls quietly educational documentary about the rise of alternative, environmentally friendly but still animal-based meat, as if to gently beckon carnivorous viewers who might be expecting a dour lecture. That isnt on the cards here, however. Meat the Future unfolds as a thorough and persuasive presentation for a cutting-edge product that it wants us to start thinking about in normalized terms; its got too much to explain and advocate to leave much time for moral repudiation. Clean meat, as cell-grown protein has been branded by the scientists developing it, is the future; Marshalls doc treats the present as a formality to be politely put behind us.

Selected to premiere as a special presentation at Hot Docs and currently streaming as part of the Toronto-based festivals online edition this smoothly assembled, information-led doc should transfer easily to television slots and VOD platforms, where itll connect with general audiences who may have encountered the subject of slaughter-free meat via buzzword-heavy magazine articles, but havent got into the chewier details. It gives us an amiable, reassuring guide in the form of Dr. Uma Valeti, an Indian-born cardiologist turned CEO of trailblazing clean meat startup Memphis Meats, who is quick to clarify what his passion product is not: Its not, he insists, lab-grown, cloned, in vitro, or any of the more daunting, clinical terms thrown around by advocates of more traditional butchery.

What it is is at once elegantly simple and kind of mind-blowing: at the edge of human knowledge, one Memphis Meats scientist claims, in a rare moment of hyperbolic extravagance. With equivalent tissue-engineering techniques to those used in regenerative medicine, scientists effectively cultivate flesh from the cells of living animals, resulting in a product allegedly closer in taste and texture to traditional meat than any plant-based alternative which is hardly surprising given the biological roots of it all, except that this technology results in no animal death or waste. Marshall doesnt glide through these nitty-gritties as if dispensing with the the science part in a shampoo commercial: Rather, the better part of the film is given over to Valeti and his colleagues repeated explanations and illustrations of how the sausage, so to speak, is made.

This may not be the stuff of exhilarating cinema, but neither is it dull. Meat the Future is a substance-over-style doc that manages the rare trick of being at once dry and rather engrossing: Over 90 minutes, its methodical, explicatory approach affords viewers of various dietary persuasions ample space to consider their own gastronomic preferences, preconceptions and prejudices. Marshall, who established her eco-doc credentials with 2013s crowdpleasing animal-rights study The Ghosts in Our Machine, isnt out to break a rhetorical sweat arguing us into a position: Like the smiling, soft-spoken Dr. Valeti, she provides enough facts and yes, in brief, horrifying footage from vast American factory farms, just enough of an emotional tug for us to argue ourselves there.

A handful of opposing views are introduced via footage from a combined FDA and USDA conference on the future branding of clean meat, prompted by protests from traditional livestock farmers that the miracle product shouldnt legally be permitted to use the m-word at all. Representatives from various American cattlemens associations many of them amusingly attired to type in Stetson hats and fringe jackets say their piece, but the film doesnt work up an argumentative head of steam. Between the cool, pale tones of its camerawork and graphics and the measured, conversational rhythm of its editing, Meat the Future aims for the same air of high-road calm as the burgeoning industry it depicts.

Still, one does wish for a slightly wider, more colorful range of perspectives here. Were treated to the impressed responses of various scientists and journalists as they chow down on cultivated meatballs, duck cutlets and clean but enticingly greasy fillet of fried chicken but the film misses a trick by not getting any restaurateurs or food personalities to weigh in on its merits. Where clean meat fits into a world increasingly drawn toward plant-based cuisine, meanwhile, is another intriguing avenue that goes unexplored: Surely the thoughts of an expert vegan advocate or two would further test and enrich the films compelling case for kinder carnivorousness.

See the article here:
Meat the Future: Film Review - Variety

The report on the Carbon Fibre Application to Biomaterials market provides a birds eye view of the current proceeding within the Carbon Fibre Application to Biomaterials market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Carbon Fibre Application to Biomaterials market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Carbon Fibre Application to Biomaterials market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

As per the presented market report, the global Carbon Fibre Application to Biomaterials market is projected to attain a CAGR growth of ~XX% during the assessment period and surpass a value of ~US$XX by the end of 20XX. Further, the report suggests that the growth of the Carbon Fibre Application to Biomaterials market hinges its hope on a range of factors including, emphasis on innovation by market players, surge in the investments pertaining to R&D activities, and favorable regulatory policies among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2568519&source=atm

Competition Landscape

The report provides critical insights related to the business operations of prominent companies operating in the Carbon Fibre Application to Biomaterials market. The revenue generated, market presence of different companies, product range, and the financials of each company is included in the report.

Regional Landscape

The regional landscape section of the report provides resourceful insights related to the scenario of the Carbon Fibre Application to Biomaterials market in the key regions. Further, the market attractiveness of each region provides players a clear understanding of the overall growth potential of the Carbon Fibre Application to Biomaterials market in each region.

End-User Analysis

The report provides a detailed analysis of the various end-users of the Carbon Fibre Application to Biomaterials along with the market share, size, and revenue generated by each end-user.

The following manufacturers are covered:ACS MaterialeSpin TechnologiesGrupo AntolinLitmus NanotechnologyCarbon Nanomaterial TechnologyGraphenanoNanographite MatericalsPyrograpg ProsuctsAIXTRONPyrograf ProductsApplied SciencesEMFUTUR Technologies

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeCarbon NanofibersOther

Segment by ApplicationRegenerative MedicineCancer TreatmentOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2568519&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2568519&licType=S&source=atm

Visit link:
Coronavirus business impact: Carbon Fibre Application to Biomaterials Market 10-year Forecast and Trends Analysis Research Report - Jewish Life News

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=1889&ltype=S

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read more here:
Regenerative Medicine Market - Rising focus on cell therapy products drive the market growth - BioSpace

Pune, May 27, 2020 (GLOBE NEWSWIRE) -- The global regenerative medicine market size is expected to reach USD 151,949.5 billion by 2026, exhibiting a CAGR of 26.1% during the forecast period. The growing R&D investment by key players for the development of innovative regenerative therapies can be a vital factor enabling the growth of the market during the forecast period, states Fortune Business Insights in a report, titled Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 2026 the market size stood at USD 23,841.5 Million in 2018. The growing organ transplantation surgeries will spur opportunities for the market during the forecast period.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Market Driver:

Escalating Cases of Genetic Disorders to Augment Growth

The increasing prevalence of chronic disorders can be an essential factor enabling the growth of the market. Similarly, the growing incidence of genetic disorders will fuel demand for the market. The growing investment in R&D activities by major market players will have a positive impact on the regenerative medicine market growth during the forecast period. For instance, in March 2018, SanBio Group, a leader in regenerative medicine and therapies for neurological disorders announced that it has made a deal with Hitachi Chemical Advanced Therapeutics Solutions, LLC, a cell manufacturing company for the development and manufacturing of innovative regenerative medicines.

Furthermore, the rising cases of neurological disorders will influence the healthy growth of the market. The growing healthcare expenditure in developed and developing countries will boost the market in the forthcoming years. The ongoing clinical trials and robust pipeline products in stem cell andgene therapy will contribute tremendously to the growth of the market. The rising utilization of skin substitutes, grafts, bone matrix, and other tissue-engineered regenerative medicine in orthopedic and neurosurgical applications will augment the growth of the market.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

Regional Analysis:

Development of Novel Therapies to Favor Growth in North America

The market in North America generated a revenue of USD 9,128.2 million in 2018 and is predicted to grow rapidly during the forecast period owing to the presence of major pharmaceutical companies. The growing launch of novel therapeutics and the availability of advanced technologies along with clinical trials will support growth in North America. Asia Pacific is expected to witness a high growth rate during the forecast period owing to the

developing healthcare infrastructure and facilities. The increasing stem cell research in developing countries such as India, Japan China will contribute positively to the growth of the market. For instance, In April 2013, the Japan Ministry of Health, Labor, and Welfare approved Regenerative Medicine law. The growing number of clinical developments of regenerative and cell-based therapies will drive the market in the region. The increasing government initiatives for human embryonic stem cell research and development will further encourage growth in the region. The surge in geriatric patients, the evolving lifestyle of people, and the growing need for novel therapies are factors likely to aid the expansion of the market in Asia Pacific.

Quick Buy - Regenerative Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100970

Key Development:

2018: Novartis announced that it has received EUs approval for one-time gene therapy Luxturna, to restore vision in people with rare and genetically-associated retinal disease.

List of the Key Companies Operating in the Regenerative Medicine Market are:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/regenerative-medicine-market-100970

Detailed Table of Content:

TOC Continued.!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

Have a Look at Related Reports:

Gene Therapy Market Size, Share and Global Trend By Disease Indication(Cancer, Genetic disorders, Cardiovascular diseases, Ophthalmology, Neurological conditions) By Type of Vectors (Viral vectors, Non-viral vectors), By Type of Cells(Somatic cells, Germline cells) and Geography Forecast till 2026

Induced Pluripotent Stem Cells Market Size, Share and Global Trend By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education & research institutes, Biotechnological companies) and Geography Forecast till 2026

Platelet Rich Plasma Market Size, Share And Global Trend By Origin (Allogeneic, Autologous, Homologous), By Type (Pure PRP, Leukocyte rich PRP, Leukocyte rich fibrin), By Application (Orthopaedic surgery, Cosmetic surgery, General surgery, Neurosurgery, Others), And Geography Forecast Till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/regenerative-medicine-market-9183

Go here to see the original:
Regenerative Medicine Market to Exhibit a CAGR of 26.1% by 2026; Rising Prevalence of Genetic Disorders to Fuel Demand, states Fortune Business...

Pessac, France Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of NextGeneration Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a bioprinted skin substitute in collaboration with the Assistance Publique Hpitaux de Marseille. Poietis appoints Dr. Geoffrey Gurtner, MD, Johnson and Johnson Professor of Surgery, Professor of Materials Science and Engineering at Stanford University and Vice-Chairman of Surgery for Innovation at Stanford University School of Medicine (California, United States) and Dr. Michael H. May, President & CEO of the Center for Commercialization of Regenerative Medicine (CCRM) at Toronto (Canada).

The formation of Poietis SAB is a very important step towards company global deployment in the clinical area says Bruno Brisson, Poietis co-founder and VP Business Development. We are delighted to welcome Dr. Gurtner and Dr. May to our SAB, where they will be key contributors in further enhancing our efforts to bring bioprinting solutions to clinicians and patients with high unmet needs.

To have Dr. Gurtner, a world-renowned expert in tissue-engineering therapies for skin wound healing, join our SAB will enrich our R&D efforts to achieve the first-in-human of a bioprinted skin substitute in the coming years adds Dr. Fabien Guillemot, CEO and Poietis founder. We also believe Dr. May will prove invaluable to Poietis leadership team, and we look forward to his insights and guidance to accelerate the advancement of our bioprinting platform technology to address the key challenges in tissue manufacturing and regenerative medicine.

3D bioprinting is a once-in-a-generation transformative technology. By focusing its 3D printing platform on a clinical application of high unmet need, Poietis is leading the adoption of 3D printing in cell therapy and tissue engineering comments Dr. Michael H. May, PhD, President & CEO of the CCRM.

Dr. Geoffrey Gurtner, MD, is Johnson and Johnson Professor of Surgery and Professor of Materials Science and Engineering at Stanford University, California; USA. He currently serves as the Associate Chairman for Research in the Department of Surgery and is the Executive Director of the Stanford Wound Care Center.

Geoff is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California-San Francisco School of Medicine. He completed a general surgery residency at Massachusetts General Hospital, a plastic surgery residency at NYU School of Medicine and received advanced training in microsurgery at the University of Texas-MD Anderson Cancer Center. He is board certified in both general surgery and plastic surgery. He is the author of over 180 peer-reviewed publications in both scientific and surgical literature and editor for two major textbooks in the field: Grabb & Smiths Plastic Surgery and Plastic Surgery. Geoff was awarded the James Barrett Brown Award (for best paper in plastic surgery) in both 2009 and 2010, and has been named Researcher of the Year by the American Society of Plastic Surgeons and the American Association of Plastic Surgeons. His research has led to the development of several novel biomedical technologies. Geoff has co-founded several start-ups focused on wound healing, aesthetics and cardiovascular health.

Dr. Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship. He is President and Chief Executive Officer of the Center for Commercialization of Regenerative Medicine (CCRM) a Canadian public-private partnership supporting the translation and commercialization of cell & gene therapies and associated enabling technologies through stakeholder networks and with specialized teams, infrastructure and funding. He is also CEO of CCRM Enterprises, the venture creation and investment arm of CCRM.

Prior to CCRM, Michael was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. Rimons initial focus was on advanced wound healing. Michael sits on a number of boards and advisory committees, including: the Entrepreneurship Leadership Council at the University of Toronto; the Commercialization Committee of the International Society for Cell and Gene Therapy, the Alliance for Regenerative Medicine Foundation, CellCan and AgeX Inc. He is Chair of ExcellThera and co-moderates sessions in the health streams of the Creative Destruction Labs.

*****

About Poietis: Bioprinting company specializing in the development of new biomanufacturing solutions, based on Laser-Assisted Bioprinting, for human tissues. Poietis mission is to provide clinicians and patients with tissue engineering therapies thanks to its innovative, proprietary Next-Generation Bioprinting platform (NGB). The multimodal NGB platform is declined in two versions: one for in vitro tissue engineering research (NGB-R) and a clinical version (NGB-C) for the production of implantable bioprinted tissues. This multi-modal, automated biomanufacturing platform enables researchers to achieve superior tissue through high resolution, and enables the fabrication of complex tissues with repeatability and reproducibility. Poietis bioprinting technology is the result of innovative research carried out over ten years at Inserm and the University of Bordeaux. Poietis won the iLab competition in 2014, the World Innovation Challenge Phase II in 2017 and recently the EY Disruptive Strategy Award. The company currently employs 35 people. More information: http://www.poietis.com Contact : bruno.brisson@poietis.com

Read more here:
Poietis Announces Formation of Scientific Advisory Board and Appoints Two First Prominent Regenerative Medicine Experts - BioSpace

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing prevalence of chronic diseases has been instrumental in driving the growth of the market.

Regenerative Medicine Market 2020-2024: Segmentation

Regenerative Medicine Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Regenerative Medicine Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our regenerative medicine market report covers the following areas:

This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.

Regenerative Medicine Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. Backed with competitive intelligence and benchmarking, our research reports on the regenerative medicine market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Regenerative Medicine Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Research Report with COVID-19 Forecasts - Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth |...